Eli Lilly will acquire the AbbVie-backed neurological disease therapy developer in a $135m transaction that could top $1.2bn with milestone payments.
Eli Lilly has agreed to buy US-based neurological disease drug developer Disarm Therapeutics for an upfront fee of $135m in a deal that will allow fellow pharmaceutical firm AbbVie to exit.
Disarm is working on treatments for neurological disorders such as multiple sclerosis or amyotrophic lateral sclerosis (ALS) that are intended to work by inhibiting the SARM1 protein, thought to be a prime driver of axonal degeneration in the early stages of such diseases.
The company was founded by venture…
